Case 2 Additional glucose-lowering drug to reach glycaemic target in cardiac patient

Prattichizzo, Francesco, PhD, IRCCS MultiMedica, Milan, Italy
La Sala, Lucia, PhD, IRCCS MultiMedica, Milan, Italy
Prof. Ceriello, Antonio MD, IRCCS MultiMedica, Milan, Italy

04 May 2020

Francesco Prattichizzo

Lucia La Sala

Antonio Ceriello

The case

Roberto Schiazza is a 68-year-old retired accountant living with his wife. He has lived with Type 2 diabetes (T2DM) for 15 years ago. His last records show a level of Glycated haemoglobin at 8.2%, a total cholesterol at 150 mg/dl, and a blood pressure at 139/95 mmHg. This solid man (182 cm – 80 kg) has just been diagnosed with heart failure with reduced ejection fraction. As medication he takes metformin 1g/day, ACE inhibitor, statin

Test your knowledge

References

Question 1:

Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V,et al. ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 202041:255-323.
Schnell O, Standl E, Catrinoiu D, Itzhak B, Lalic N, Rahelic D, Skrha J, Valensi P, Ceriello A. Report from the 4th Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group. Cardiovasc Diabetol. 2019 Mar 11;18(1):30. doi: 10.1186/s12933-019-0822-4.
Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019 Jan 5;393(10166):31-39.

Question 2:

Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V,et al. ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 202041:255-323.
Gomez-Peralta F, Abreu C, Lecube A, Bellido D, Soto A, Morales C, Brito-Sanfiel M, Umpierrez G. Practical Approach to Initiating SGLT2 Inhibitors in Type 2 Diabetes. Diabetes Ther. 2017 Oct;8(5):953-962. doi: 10.1007/s13300-017-0277-0.
Schnell O, Standl E, Catrinoiu D, Itzhak B, Lalic N, Rahelic D, Skrha J, Valensi P, Ceriello A. Report from the 4th Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group. Cardiovasc Diabetol. 2019 Mar 11;18(1):30. doi: 10.1186/s12933-019-0822-4.
Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019 Jan 5;393(10166):31-39.

Show navigation Hide navigation